AI Ophthalmology and Optometry | Altris AI

AI for Dry AMD

Book free trial to see how AI can detect Dry AMD and 70+ other pathologies/biomarkers

Book Intro AI Ophthalmology and Optometry | Altris AI

Altris AI is an AI Decision Support for OCT Analysis that leverages objective AI for Dry AMD (dAMD) detection and comprehensive progression monitoring.

Immediate detection of common Dry AMD biomarkers—Confluent Drusen, Hard Drusen, Soft Drusen, and Reticular Pseudodrusen, RPE Atrophy, and Hypertransmission—as well as less typical ones, including Neurosensory Retina Atrophy, Vitelliform Material, and Chorioretinal Scar.

Objective measurement of individual Dry AMD biomarkers, with their locations visualized on ETDRS grids and B-scans.

Precise tracking of drusen changes for treatment response assessment, through dedicated Drusen Count feature.

AI-powered analysis of dAMD transforms raw information from OCT scans into structured, research-ready data.

Platform overview

Only practical features for eye care specialists and clinical research

GDPR compliant (all data is encrypted), CE-certified, and FDA- cleared (510k).

Alisdair Buchanan Clinical Director

As someone already confident in interpreting scans, I didn’t need help understanding OCT—but Altris AI provides something even more valuable: a kind of second opinion. It supports my clinical decisions and offers an added layer of reassurance, particularly in borderline or complex cases. That’s not just helpful—it’s powerful.

7 May, 2025

William C. Fruchtman, Optometry Owner

I was really excited to find Altris AI to bolster my skills identifying certain macular diseases. It's a great program and has guided me in the diagnosis of complex cases.

3 Oct, 2024

Scott Sedlacek Optometry Owner

Altris AI identified and described pathology that I could not. Early detection changes the treatment from doing nothing to something. Also, Altris AI described something that I thought was worse than it was. Saved me from over-referring. Patients love to see the color-coded images which help as an educational tool and get buy-in on the treatment plan which helps compliance.

1 Feb, 2024

Richard Clare Optometry Owner

We are adding a new OCT to one of our practices and may benefit from some extra support with AI to speed up the interpretation of results and assist the busy Optometry team.

Dec 7, 2023

Immediately and precisely track how Dry AMD is changing based on biomarker progression. Explore automated comparisons of patient data from multiple visits through percentages, maps, and graphs. Use the dedicated Drusen Count feature to identify drusen type, volume, area, size, and monitor changes longitudinally.

Leverage error-free, reproducible measurements to determine the optimal treatment course.

Accelerated workflow with immediate, automated Dry AMD biomarkers identification.
Objective dAMD biomarker measurements for precise trial actions.
Clinical insights into changes over time through intuitive visuals for biomarker quantification and localization.
Clear assessment of the effectiveness of photobiomodulation through Drusen Count measurements.

Add OCT examinations from different visits

Identify Dry AMD biomarkers with color-coding

Explore the area and volume of biomarkers

Track how dAMD changes over time in the Progression module

How Altris AI works?

And what makes this AI the leading solution for Dry AMD detection and management?

Altris AI is a web platform created by retina experts for all eye care specialists and clinicians.

We’ve collected millions of OCT scans, and our team graphically labeled thousands of them to create the Altris AI system that can:

Detect 70+ pathologies and biomarkers, including dAMD biomarkers.

Measure and track pathological changes across multiple examinations.

Monitor the progression of Dry AMD for better patient outcomes.

Get clinical insights with the help of objective measurements.

Formats

DICOM format will help you to extract maximum information. However, the system works with all data formats, such as jpg, and png

OCT equipment

Altris AI is vendor-neutral. We work with all the OCT equipment producers

OCT reports

We create comprehensible OCT reports for patients and doctors

For clinical research

What you get with Altris AI:

Accelerate ophthalmic drug trial with AI
Detect Dry AMD, nAMD, Geographic atrophy and their biomarkers ( +70 retinal pathologies and biomarkers)
Track the progression of biomarkers to assess drug efficiency
Enroll the right patients based on fast biomarkers detection
Reduce costs associated with manual scan review with automated analysis

For eye care

We support you through the whole way

14 Days of Free Trial to see the value
Support during the whole trial period
Early glaucoma assessment module access
CE-certified, GDPR, HIPAA compliant, FDA clearance
Integration support with any EHR, EMR system.
Cloud data storage/on premises possible
Access to the whole functional during trial

Contact us

Ask us any question

For a clinic or an optometry: we will show the system to you during 15-minute call and then you will have a free trial to test it yourself.

Book intro + free trial

Any eye care practitioner can test it for a personal use for free

Demo